<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11159">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02961673</url>
  </required_header>
  <id_info>
    <org_study_id>HU-014_P1/2</org_study_id>
    <nct_id>NCT02961673</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines</brief_title>
  <official_title>A Phase I/Ⅱ Clinical Trial to Compare the Safety and Efficacy of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huons Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huons Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I/Ⅱ Clinical Trial to Compare the Safety and Efficacy of HU-014 versus Botox® in
      Subject with Moderate to Severe Glabellar Lines
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Treatment-Emergent Adverse events (TEAs), Adverse Drug Reactions (ADRs) and Serious Adverse Events (SAEs) after injecting Investigational Product(Phase 1)</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline of Glabellar Lines improvement rate(Frown)</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Columbia Suicide Severity Rating Scale(C-SSRS)</measure>
    <time_frame>Week 4, Week 8, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from Baseline of Glabellar Lines improvement rate (Frown)</measure>
    <time_frame>Week 8, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from Baseline of Glabellar Lines improvement rate (Not frown)</measure>
    <time_frame>Week4, Week 8, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Outcome Measure (Phase 2) by colleting Subject Satisfaction assessment</measure>
    <time_frame>Week 4, Week 8, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of TEAs (Treatment-Emergent Adverse events), ADRs (Adverse Drug Reactions) and SAEs (Serious Adverse Events) after injecting Investigational Product</measure>
    <time_frame>Week 4, Week 8, Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Glabellar Lines</condition>
  <arm_group>
    <arm_group_label>HU-014 Inj(Phase 1 and 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HU-014 Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botox Inj(Phase 2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Botox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HU-014 Inj</intervention_name>
    <description>Clostridium botulinum type A</description>
    <arm_group_label>HU-014 Inj(Phase 1 and 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Botox Inj</intervention_name>
    <description>Clostridium botulinum type A</description>
    <arm_group_label>Botox Inj(Phase 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Facial Wrinkle Scale (FWS) score &gt; 2 when Subject knits brow extremely

        Exclusion Criteria:

          -  Volunteer who has history of any diseases following. (myasthenia gravis,
             Eaton-Lambert syndrome, amyotrophic lateral sclerosis etc.)

          -  From screening, Subject who get a plastic Surgery including fascioplasty, Prosthesis
             implantation within 6 Weeks

          -  Subject who has skin disorder including infection and scar on injection site

          -  Subject who takes a medication including skeletal muscle relaxants, Aminoglycoside,
             lincomycin, anticholinergic drug, benzodiazepine, benzamide etc.

          -  Subject who takes a medication including anticoagulant, antithrombotic drug except
             low dose aspirin (below 325 mg/day)

          -  Any condition that, in the view of the investigator, would interfere with study
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jungmin Lee, Researcher</last_name>
    <email>jungmin2533@huons.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huons</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13486</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huons</last_name>
      <phone>82-70-7492-5149</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 8, 2016</lastchanged_date>
  <firstreceived_date>September 26, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
